The latest price target for Chemomab Therapeutics (NASDAQ:CMMB) was reported by Oppenheimer on November 15, 2024. The analyst firm set a price target for $11.00 expecting CMMB to rise to within 12 months (a possible 574.85% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Chemomab Therapeutics (NASDAQ:CMMB) was provided by Oppenheimer, and Chemomab Therapeutics reiterated their outperform rating.

The last upgrade for Chemomab Therapeutics Ltd happened on May 6, 2024 when Oppenheimer raised their price target to $6. Oppenheimer previously had a perform for Chemomab Therapeutics Ltd.

The last downgrade for Chemomab Therapeutics Ltd happened on June 7, 2023 when Oppenheimer changed their price target from N/A to N/A for Chemomab Therapeutics Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemomab Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemomab Therapeutics was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Chemomab Therapeutics (CMMB) rating was a reiterated with a price target of $13.00 to $11.00. The current price Chemomab Therapeutics (CMMB) is trading at is $1.63, which is out of the analyst’s predicted range.